1-Deoxynojirimycin
In clinical developmentAlso known as DNJ, Duvoglustat, D-1-deoxynojirimycin, Deoxynojirimycin+4 more
DNJ, Duvoglustat, D-1-deoxynojirimycin, Deoxynojirimycin, (+)-1-Deoxynojirimycin, 1 deoxynojirimycin, 1,5-dideoxy-1,5-imino-D-glucitol, 5-amino-1,5-dideoxy-D-glucopyranose.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Journals, researchers & institutions
- Orphanet journal of rare diseases1
- Brassier A1
- Broué P1
- Cances C1
- Chabrol B1
- Dahmani-Rabehi B1
- Eyer D1
- Freihuber C1
- Héron B1
- Department of Clinical Biochemistry1
- Haguenau Hospital1
- INSERM U1037 (Cancer Research Centre of Toulouse)1
- Jean Verdier University Hospital1
- Kremlin-Bicêtre University Hospital1
- La Timone University Hospital1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as 1-Deoxynojirimycin in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials